Get the Stockscreener App
7.5233
0.74%
0.0433
Iteos Therapeutics Inc stock is traded at $7.5233, with a volume of 24,071.
It is up +0.74% in the last 24 hours and down -6.51% over the past month.
ITeos Therapeutics Inc is a biopharmaceutical company. It designs novel product candidates with optimized pharmacologic properties to improve clinical outcomes by restoring the immune response against cancer. The company's product candidates include EOS-850 which is an Adenosine A2A receptor-specific antagonist, EOS-448 which is an ADCC-enabled, anti-TIGIT immune checkpoint blocking antibody among other drug candidates.
See More
Previous Close:
$7.48
Open:
$7.56
24h Volume:
24,071
Relative Volume:
0.06
Market Cap:
$273.27M
Revenue:
$127.70M
Net Income/Loss:
$-121.25M
P/E Ratio:
-2.3883
EPS:
-3.15
Net Cash Flow:
$-120.32M
1W Performance:
+1.82%
1M Performance:
-6.51%
6M Performance:
-56.97%
1Y Performance:
-28.58%
1-Day Range:
$7.52
$7.63
1-Week Range:
$7.395
$7.63
52-Week Range:
$7.06
$18.75
Iteos Therapeutics Inc Stock (ITOS) Company Profile
Name
Iteos Therapeutics Inc
Sector
Industry
Phone
857-204-4583
Address
321 ARSENAL STREET, WATERTOWN
Compare ITOS with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ITOS
Iteos Therapeutics Inc
|
7.52 | 273.27M | 127.70M | -121.25M | -120.32M | -3.15 |
|
VRTX
Vertex Pharmaceuticals Inc
|
480.76 | 123.34B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
696.46 | 76.09B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
648.71 | 39.34B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
252.00 | 32.49B | 2.25B | -278.16M | -42.59M | -2.17 |
|
BNTX
Biontech Se Adr
|
117.10 | 28.26B | 3.30B | -501.07M | 1.03B | -2.1146 |
Iteos Therapeutics Inc Stock (ITOS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Aug-13-24 | Initiated | Wells Fargo | Overweight |
| May-05-21 | Initiated | H.C. Wainwright | Buy |
| Oct-08-20 | Initiated | Robert W. Baird | Outperform |
| Aug-18-20 | Initiated | JP Morgan | Overweight |
| Aug-18-20 | Initiated | Piper Sandler | Overweight |
| Aug-18-20 | Initiated | SVB Leerink | Outperform |
| Aug-18-20 | Initiated | Wedbush | Outperform |
View All
Iteos Therapeutics Inc Stock (ITOS) Latest News
Short Interest in iTeos Therapeutics, Inc. (NASDAQ:ITOS) Increases By 5.2% - MarketBeat
Empowered Funds LLC Grows Stock Holdings in iTeos Therapeutics, Inc. (NASDAQ:ITOS) - Defense World
Short Interest in iTeos Therapeutics, Inc. (NASDAQ:ITOS) Grows By 5.2% - Defense World
(ITOS) Investment Analysis and Advice - Stock Traders Daily
Peapod Lane Capital LLC Invests $836,000 in iTeos Therapeutics, Inc. (NASDAQ:ITOS) - MarketBeat
ITOS stock touches 52-week low at $7.09 amid market challenges - MSN
iTeos Therapeutics, Inc. (NASDAQ:ITOS) Shares Acquired by SG Americas Securities LLC - Defense World
When (ITOS) Moves Investors should Listen - Stock Traders Daily
We Think iTeos Therapeutics (NASDAQ:ITOS) Needs To Drive Business Growth Carefully - Yahoo Finance
iTeos Therapeutics, Inc. (NASDAQ:ITOS) Sees Significant Decline in Short Interest - MarketBeat
(ITOS) Proactive Strategies - Stock Traders Daily
JPMorgan Chase & Co. Purchases 5,368 Shares of iTeos Therapeutics, Inc. (NASDAQ:ITOS) - Defense World
HC Wainwright Reaffirms “Buy” Rating for iTeos Therapeutics (NASDAQ:ITOS) - Defense World
Short Interest in iTeos Therapeutics, Inc. (NASDAQ:ITOS) Declines By 21.1% - MarketBeat
All You Need to Know About iTeos Therapeutics (ITOS) Rating Upgrade to Buy - MSN
iTeos Therapeutics' (ITOS) "Buy" Rating Reaffirmed at HC Wainwright - MarketBeat
(ITOS) On The My Stocks Page - Stock Traders Daily
Barclays PLC Has $1.16 Million Holdings in iTeos Therapeutics, Inc. (NASDAQ:ITOS) - Defense World
Invivyd (NASDAQ:IVVD) vs. iTeos Therapeutics (NASDAQ:ITOS) Head-To-Head Comparison - Defense World
Iteos Therapeutics advances anti-TREM2 monoclonal antibody toward IND filing - BioWorld Online
iTeos Therapeutics Plans 2025 Data Presentation on Therapies - TipRanks
iTeos Therapeutics to raise $120 million via registered direct offering - MSN
Wedbush Reaffirms Outperform Rating for iTeos Therapeutics (NASDAQ:ITOS) - Defense World
iTeos to Present at the 43rd Annual J.P. Morgan Healthcare Conference - Informazione.it
iTeos annonce ses priorités stratégiques et ses étapes clés prévues pour 2025 - GlobeNewswire Inc.
iTeos Announces 2025 Strategic Priorities and Anticipated Milestones - GlobeNewswire
iTeos Therapeutics' (ITOS) "Outperform" Rating Reaffirmed at Wedbush - MarketBeat
iTeos Unveils Ambitious 2025 Cancer Drug Pipeline: Multiple Phase 2 Readouts, $684M Cash Runway - StockTitan
iTeos Therapeutics CEO to Present at J.P. Morgan Healthcare Conference 2025 - StockTitan
Trading (ITOS) With Integrated Risk Controls - Stock Traders Daily
iTeos Therapeutics, Inc. (NASDAQ:ITOS) Shares Bought by Geode Capital Management LLC - Defense World
iTeos Therapeutics, Inc. (NASDAQ:ITOS) Holdings Trimmed by Franklin Resources Inc. - Defense World
iTeos Therapeutics, Inc. (NASDAQ:ITOS) Stock Holdings Lessened by Barclays PLC - Defense World
Reviewing Calidi Biotherapeutics (NYSE:CLDI) & iTeos Therapeutics (NASDAQ:ITOS) - Defense World
State Street Corp Increases Holdings in iTeos Therapeutics, Inc. (NASDAQ:ITOS) - Defense World
State Street Corp Increases Position in iTeos Therapeutics, Inc. (NASDAQ:ITOS) - MarketBeat
Trend Tracker for (ITOS) - Stock Traders Daily
Wells Fargo & Company Has Lowered Expectations for iTeos Therapeutics (NASDAQ:ITOS) Stock Price - Defense World
iTeos Therapeutics, Inc. (NASDAQ:ITOS) Shares Sold by UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC - Defense World
iTeos Therapeutics price target lowered to $19 from $31 at Wells Fargo - Yahoo Finance
iTeos Therapeutics (NASDAQ:ITOS) Price Target Cut to $19.00 by Analysts at Wells Fargo & Company - MarketBeat
Inupadenant “deprioritised” by iTeos in favour of pipeline TIGIT therapy - MSN
Merck, iTeos dropping assets, Viridian data — BioCentury’s Clinical Report - BioCentury
iTeos Therapeutics: A Perhaps Unjustified Decline To End 2024 - Seeking Alpha
Merck & Co. Calls Time On Flop TIGIT And LAG-3 Programs - News & Insights
Charles Schwab Investment Management Inc. Buys 8,397 Shares of iTeos Therapeutics, Inc. (NASDAQ:ITOS) - Defense World
iTeos Therapeutics’ (ITOS) Buy Rating Reiterated at HC Wainwright - Defense World
Wedbush Reaffirms “Outperform” Rating for iTeos Therapeutics (NASDAQ:ITOS) - Defense World
Iteos Therapeutics Inc Stock (ITOS) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.42%
0.04%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):